Literature DB >> 23824372

Antianaerobic antimicrobials: spectrum and susceptibility testing.

Itzhak Brook1, Hannah M Wexler, Ellie J C Goldstein.   

Abstract

Susceptibility testing of anaerobic bacteria recovered from selected cases can influence the choice of antimicrobial therapy. The Clinical and Laboratory Standards Institute (CLSI) has standardized many laboratory procedures, including anaerobic susceptibility testing (AST), and has published documents for AST. The standardization of testing methods by the CLSI allows comparisons of resistance trends among various laboratories. Susceptibility testing should be performed on organisms recovered from sterile body sites, those that are isolated in pure culture, or those that are clinically important and have variable or unique susceptibility patterns. Organisms that should be considered for individual isolate testing include highly virulent pathogens for which susceptibility cannot be predicted, such as Bacteroides, Prevotella, Fusobacterium, and Clostridium spp.; Bilophila wadsworthia; and Sutterella wadsworthensis. This review describes the current methods for AST in research and reference laboratories. These methods include the use of agar dilution, broth microdilution, Etest, and the spiral gradient endpoint system. The antimicrobials potentially effective against anaerobic bacteria include beta-lactams, combinations of beta-lactams and beta-lactamase inhibitors, metronidazole, chloramphenicol, clindamycin, macrolides, tetracyclines, and fluoroquinolones. The spectrum of efficacy, antimicrobial resistance mechanisms, and resistance patterns against these agents are described.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23824372      PMCID: PMC3719496          DOI: 10.1128/CMR.00086-12

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  139 in total

1.  Investigation of the prevalence of tetQ, tetX and tetX1 genes in Bacteroides strains with elevated tigecycline minimum inhibitory concentrations.

Authors:  Noémi Anikó Bartha; József Sóki; Edit Urbán; Elisabeth Nagy
Journal:  Int J Antimicrob Agents       Date:  2011-10-19       Impact factor: 5.283

2.  The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.

Authors:  E J Ellis-Grosse; T Babinchak; N Dartois; G Rose; E Loh
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

3.  Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009.

Authors:  D R Snydman; N V Jacobus; L A McDermott; Y Golan; E J C Goldstein; L Harrell; S Jenkins; D Newton; C Pierson; J Rosenblatt; R Venezia; S L Gorbach; A M Queenan; D W Hecht
Journal:  Anaerobe       Date:  2011-06-02       Impact factor: 3.331

Review 4.  Anaerobic infections: update on treatment considerations.

Authors:  Elisabeth Nagy
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

Review 5.  Tigecycline: a new glycylcycline antimicrobial.

Authors:  M L Townsend; M W Pound; R H Drew
Journal:  Int J Clin Pract       Date:  2006-12       Impact factor: 2.503

6.  Incidence and clinical significance of anaerobic bacteraemia in cancer patients: a 6-year retrospective study.

Authors:  J-R Zahar; H Farhat; E Chachaty; P Meshaka; S Antoun; G Nitenberg
Journal:  Clin Microbiol Infect       Date:  2005-09       Impact factor: 8.067

7.  Evaluation of the Etest for antimicrobial spectrum and potency determinations of anaerobes associated with bacterial vaginosis and peritonitis.

Authors:  J L Croco; M E Erwin; J M Jennings; L R Putnam; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1994-12       Impact factor: 2.803

8.  Clinical significance and outcome of anaerobic bacteremia.

Authors:  J H Salonen; E Eerola; O Meurman
Journal:  Clin Infect Dis       Date:  1998-06       Impact factor: 9.079

9.  Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.

Authors:  Joseph S Solomkin; John E Mazuski; John S Bradley; Keith A Rodvold; Ellie J C Goldstein; Ellen J Baron; Patrick J O'Neill; Anthony W Chow; E Patchen Dellinger; Soumitra R Eachempati; Sherwood Gorbach; Mary Hilfiker; Addison K May; Avery B Nathens; Robert G Sawyer; John G Bartlett
Journal:  Clin Infect Dis       Date:  2010-01-15       Impact factor: 9.079

10.  In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.

Authors:  Charles E Edmiston; Candace J Krepel; Gary R Seabrook; Lewis R Somberg; Atilla Nakeeb; Robert A Cambria; Jonathan B Towne
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

View more
  73 in total

1.  High Heterogeneity of Multidrug-Resistant Enterobacteriaceae Fecal Levels in Hospitalized Patients Is Partially Driven by Intravenous β-Lactams.

Authors:  Eva M González-Barberá; Jaime Sanz; Ana Djukovic; Alejandro Artacho; Iván Peñaranda; Beatriz Herrera; María José Garzón; Miguel Salavert; José Luis López-Hontangas; Karina B Xavier; Bernhard Kuster; Laurent Debrauwer; Jean-Marc Rolain; Miguel A Sanz; Joao B Xavier; Carles Ubeda
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 2.  Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.

Authors:  Zhong Peng; Dazhi Jin; Hyeun Bum Kim; Charles W Stratton; Bin Wu; Yi-Wei Tang; Xingmin Sun
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

Review 3.  Propionibacterium acnes: from commensal to opportunistic biofilm-associated implant pathogen.

Authors:  Yvonne Achermann; Ellie J C Goldstein; Tom Coenye; Mark E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

4.  Adaptable microfluidic system for single-cell pathogen classification and antimicrobial susceptibility testing.

Authors:  Hui Li; Peter Torab; Kathleen E Mach; Christine Surrette; Matthew R England; David W Craft; Neal J Thomas; Joseph C Liao; Chris Puleo; Pak Kin Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-08       Impact factor: 11.205

5.  A comparison of Sensititre™ Anaerobe MIC plate with ATB ANA® test for the routine susceptibility testing of common anaerobe pathogens.

Authors:  Abdessalam Cherkaoui; Adrien Fischer; Nouria Azam; Arnaud Riat; Jacques Schrenzel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-06       Impact factor: 3.267

6.  Clostridial Infections in Children: Spectrum and Management.

Authors:  Itzhak Brook
Journal:  Curr Infect Dis Rep       Date:  2015-11       Impact factor: 3.725

7.  Prognostic Indicators of Recurrence of Bacterial Vaginosis.

Authors:  Jack D Sobel; Navkiranjot Kaur; Nicole A Woznicki; Dina Boikov; Tina Aguin; Gurveer Gill; Robert A Akins
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

Review 8.  Applying Pharmacodynamics and Antimicrobial Stewardship to Pediatric Preseptal and Orbital Cellulitis.

Authors:  Grant T Stimes; Jennifer E Girotto
Journal:  Paediatr Drugs       Date:  2019-12       Impact factor: 3.022

9.  Infections caused by Fusobacterium in children: a 14-year single-center experience.

Authors:  Oded Shamriz; Dan Engelhard; Violeta Temper; Shoshana Revel-Vilk; Shmuel Benenson; Rebecca Brooks; Ariel Tenenbaum; Polina Stepensky; Benjamin Koplewitz; Michal Kaufmann; Diana Averbuch
Journal:  Infection       Date:  2015-05-01       Impact factor: 3.553

10.  Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.

Authors:  N J Ajami; J L Cope; M C Wong; J F Petrosino; L Chesnel
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.